Proqr Therapeutics N.V. key statistics and ratios

In fiscal 2025, Proqr Therapeutics N.V. had return on equity of -63.8%, an operating margin of -273.1%, debt equal to 9.9% of equity and a current ratio of 3.09. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Proqr Therapeutics N.V.: financial ratios, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Operating margin	<−999%	<−999%	−489.1%	−161.2%	−273.1%
Net margin	<−999%	<−999%	−431.7%	−146.9%	−265.2%
Free-cash-flow margin	<−999%	<−999%	309.7%	−200.0%	−338.3%
Return on equity	−55.8%	−67.7%	−51.8%	−43.7%	−63.8%
Return on assets	−30.3%	−32.3%	−18.1%	−18.4%	−31.2%
Asset turnover	0.01	0.02	0.04	0.13	0.12
Current ratio	6.94	7.36	3.54	3.95	3.09
Debt to equity	38.7%	10.1%	10.4%	5.2%	9.9%
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	>999%	>999%	386.1%	192.3%	281.2%
Capital spending as % of revenue	36.3%	19.7%	21.0%	7.5%	6.4%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · December 31, 2025

What it owns · $132m

Short-term assets $118mLonger-term assets $15m

What it owes, and who funded it · $132m

Short-term liabilities $38mLonger-term liabilities $36mShareholders' equity $58m

Short-term assets cover short-term liabilities $118m of assets due within a year against $38m of liabilities due within a year.
Short-term assets cover long-term liabilities $118m short-term assets against $36m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$49m against $1m of interest.

From Proqr Therapeutics N.V.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CTMX vs PRQR CELU vs PRQR PRQR vs SCYX KROS vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Proqr Therapeutics N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Proqr Therapeutics N.V.